Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No Useful Information
With the journal article, everything changes.
A Journal Article Will Impress Equity Buyers
Yes, but FDA does read journal articles.
The Article Will Be Anavex's Real Start
Merely a listing....
The Economics of Prophylaxis and Enduring Neuron Restoration
"Right-to-Try" a good idea. But doesn't work.
Well, I was wrong. Too many zeros.
My number was right.
It's Been a Wait. But, now...!
Future Dividends (Maybe)
Don't read the rest of this. All pure conjecture. Right now, only for a moment's fun.
Ok, in five years Anavex could potentially have annual revenues of $100,000,000,000, a hundred billion.
I'll then presume that 20% of those revenues drop down and go out as dividends. That would be $20,000,000,000 each year.
That would have to be divided up for all of the outstanding shares, which I'll presume to be at the time 100,000,000, one hundred million.
With those numbers, the annual per-share dividend would be $2000.
With my few thousand AVXLs, I'll quickly be a millionaire, many times over.
At this very moment a share of AVXL is being offered for $9.3779. Round that to $9.38. If someone were to buy a thousand dollars' worth of AVXL, at that price, he or she would own 106 shares of Anavex Life Sciences Corp. That someday might be an annual dividend total of $212,000.
Safety and efficacy, yes. Approval? Yet to happen.
Anavex and Blarcamesine Are Validated
Simufilam Won't Be a Competitor
I'm Awaiting Anavex's Competition
Bigger, Still....
Drug Ps and Qs
Blarcamesine works better and bigger than perceived.
Dizziness was not a disqualifying problem.
Better, even, than aspirin.
The Anavex hypertension cohort n = 236.
Another Anavex Success
Well, Anavex gets a patent for blarcamesine as a hypertension (high blood pressure) therapy. Who could have imagined it?
Me, actually. Not at all unexpected, given the drug’s ability to safely modulate and restore a wide variety of homeostatic processes, both in cells themselves, and in tissues and organ systems. There will be more revelations of a similar nature in the future. Anavex knows more than most can imagine about their unique new candidate drugs.
Two key points. First, unlike most drugs blarcamesine acts at the top, at the start, “upstream” of cell, tissue, and organ-level processes that can be disrupted to cause disease.
Secondly, do you suppose blood pressure readings have been taken rather frequently in the hundreds of patients in clinical trials involving blarcamesine? The office nurse takes your blood pressure every time you stop in your general practitioner’s office. Simply, blood pressures are taken universally in medicine, surely in clinical trials of new or candidate drugs.
Consequently, Anavex has copious records of how blood pressure was affected when blarcamesine was taken.
Then, of course, is the absolute safety of the drug. Not a single case of drug-induced mortality or severe side effects.
The potential market size for a safe, successful hypertension drug in the US is, shall we say, large.
Close, but not as good.
What was the clue?
Once Again, an Anti-Amyloid MAB Fails.
An anti-amyloid monoclonal antibody therapy for Alzheimer’s has proven to fail, but that doesn’t deter the “amyloid is it” crowd in Alzheimer’s research. The drug is Solanezumab. Here’s a statement on what clinical results research have shown for the drug:
Yes, Aricept attaches to the sigma-1 protein. But....
Aricept is downstream, doesn't fix things.
Anavex competition drug may have caused a death.
I just read a report in this morning’s Science, journal of the American Association for the Advancement of Science (AAAS) indicating that lecanemab may have caused an Alzheimer’s patient’s death:
A simple mention? Or details?
But, should we wonder?
"Be Careful"
Ok, What Will Be the Real Anavex Revs?
Punch the numbers on a spreadsheet.
Some Anavex Arithmetic
From MayoMobile’s post, on projected Anavex annual revenues from the sale of blarcamesine to treat Alzheimer’s in the US:
Just As Expected Blarcamesene Fails Again
Ok, Here's the Data from the Indian study.
Dose Titration Probably Required for All Treatments
Thinking Outside of the Constraining RCT Box
Well, thank you for posting this account of the medical professor fixing his alcoholism with baclofen. I was not aware of the fellow nor baclofen's ability to treat alcoholic dysfunction.
But, I'm not surprised by how the fellow figured it out.
It's An Insurance Thing.